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Clinical presentation
The female proband (III:9, Figure S5 ) presented at the age of 4 years with two episodes of transient left sided weakness and aphasia, brought on by excitement. Both episodes resolved completely. She also had a long-standing history of alternate day headache, without other associated features. She underwent brain magnetic resonance imaging, and subsequently cerebral angiography (Supplementary Figure S1 ) that confirmed the diagnosis of bilateral Moyamoya disease (MMD) . She was commenced on aspirin, underwent right sided pial synangiosis and has subsequently remained clinically and radiologically stable for over 5 years. Of note, there was a positive family history of MMD in at least 2 generations on her paternal side ( Figure S5 ). Her paternal grandmother (I:2) was diagnosed with MMD and died aged 65 years. Her father (II:8) had brain imaging for investigation of epilepsy that did not show evidence of MMD. Her paternal aunt (II:1) had 3 children; she was unaffected as was her youngest son (III:3). However her other 2 children (III:1 and III:2) had a diagnosis of MMD, having presented with stroke aged 5 and a movement disorder, respectively. The paternal uncle (II:5, clinically unaffected) had a child who died from a brain haemorrhage aged 7 years although no formal diagnosis of MMD is recorded. Another paternal aunt (II:7) has a diagnosis of MMD, having suffered a stroke at the age of 21. Finally the other paternal aunt, (II:3) had 3 sons. One of the sons (III:4) was under investigation for learning difficulties, without current diagnosis, and the remaining sons (III:5 and III:6) were in good health.
Supplementary Text S2. (Fukui, 1997; Hashimoto et al., 2012) were used for diagnosis of MMD in the affected members of the family and include all of the following items based on the conventional angiographic findings: (i) stenosis or occlusion of the terminal portion of the intracranial internal carotid artery or proximal portions of the anterior cerebral artery and/or the middle cerebral artery, (ii) development of abnormal vascular networks near the occlusive or stenotic lesions in the arterial phase, (iii) bilaterality of findings (i) and (ii).
Methods

Diagnosis of
Whole exome sequencing and alignment: Whole exome capture and sequencing was performed at BGI (Shenzhen, China) using SureSelect Human All Exon v4 51 Mb kit (Agilent Technologies, Santa Clara, CA, USA) and Illumina HiSeq2000 System (Illumina, San Diego, CA, USA). We aimed for a mean coverage of 100× for the exome capture target regions. Sequencing reads were aligned with Burrows-Wheeler Aligner (BWA) v0.7.17 (Li and Durbin, 2010) to human genome build 38 (GRCh38.p1) not including alternate assemblies (GCA_000001405.15_GRCh38_no_alt_analysis_set.fna) and read duplicates were marked with Sambamba (Tarasov et al., 2015) .
Variant calling and annotation: Variant calling across the exome capture target regions with 100 bp padding was performed using Genome Analysis Toolkit (GATK) v4.0.3.0 (De-Pristo et al., 2011; McKenna et al., 2010) according to the best practices workflow for joint (multi-sample) calling (Van der Auwera et al., 2013) . The result variants were normalized and decomposed using Bcftools v1.8 (https://github.com/samtools/bcftools) and annotated with ANNOVAR (Wang et al., 2010) and dbNSFP v4.0b1 Dong et al., 2014; Liu et al., 2016) .
Variant filtering: Rare variants were defined as those having an allele frequency lower than 0.5% in public databases: ExAC (v0.3.1) (Lek et al., 2016) , gnomAD (v2.0.2) (Lek et al., 2016) , 1000 Genomes (phase 3) (1000 Genomes Project Consortium et al., 2015 and NHLBI ESP (ESP6500SI-V2; evs.gs.washington.edu/EVS/). Genotype requirements for autosomal dominant mode of inheritance were following: (i) all affecteds must be heterozygous (0/1), (ii) no unaffected can be heterozygous (0/1) or homozygous alternate (1/1), (iii) if there is incomplete penetrance suspected in the kindred with unaffected obligate carriers, these individuals must be considered affected (0/1). Genotype requirements for X-linked dominant mode of inheritance were following: (i) affected males are heterozygous (0/1) or homozygous alternate (1/1), (ii) affected females must be heterozygous (0/1), (iii) unaffecteds must be homozygous reference (0/0).
Variant interpretation:
The modified criteria from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines were used for variant classification (Richards et al., 2015; Gelb et al., 2018) . Pathogenicity and benign evidence tags was input into ClinGen Pathogenicity Calculator (Patel et al., 2017) for assessing pathogenicity of genetic variants.
Sanger sequencing: PCR amplicon sequencing was used to verify the presence of each mutation and to perform segregation analysis. The target region was amplified using primers (forward 5 -TCCACAGTCACATTGGCGACT-3 and reverse 5 -AGCCCAGTAGTAGTCTATTCG-3 ). PCR products were purified with ExoSap and sequenced using Big Dye Terminator Cycle Sequencing Kit v3.1 (Life Technologies, Foster City, CA, USA). Result electropherograms were analyzed with Geneious software (Biomatters Ltd., Auckland, New Zealand).
Supplementary Text S3.
Variant analysis
To identify a causative variant in the family affected with MMD over three generations, we performed whole exome sequencing of five family members: II:8 (father), II:9 (mother), III:1 (cousin), III:8 (sister) and III:9 (proband). We focused our analysis on rare (allele frequency <0.5% or absent in public databases) variants (SNVs and indels) within RefSeqGene exonic and splice regions, as annotated by ANNOVAR (Wang et al., 2010) . We promptly excluded the possibility of MMD being caused in this family by de novo mutations because its occurence in three generations. We also ruled out the possibility of autosomal recessive mode of inheritance because parental consanguinity was absent in the family and MMD occurred in three first cousins from two different marriages. X-linked recessive, Y-linked and mitochondrial modes of inheritance were excluded as well because both sexes were affected (with more affected females than males) and the disease appeared to be transmitted by either sex, including male-to-female. The most compatible mode of inheritance was found to be either X-linked dominant (XLD) or autosomal dominant (AD) since both sexes in subsequenct generations were affected with the same disease.
Because the pedigree was not fully consistent with AD or XLD mode, we suspected incomplete penetrance of the condition, supported by previous studies on MMD inheritance (Mineharu et al., 2006 (Mineharu et al., , 2008 . Since the affected proband (III:9) most likely inherited the condition from her father (II:8) with a family history of MMD, we assumed that the father was an asymptomatic carrier of a dominant defective allele. Moreover, although the father did not have MMD per se, he had epilepsy which can be one of the clinical presentations of MMD (Cho and Tominaga, 2010; Koizumi et al., 2017) . We applied the same assumption to the unaffected sister (III:8) that could have either 0/0 or 0/1 genotype. Assuming AD or XLD mode of inheritance with incomplete penetrance, the unaffected mother (II:9) was the only individual not related to the index case (I:2) and served as a control (genotype 0/0), while the father (II:8), the affected cousin (III:1), the sister (III:8) and the affected proband (III:9) were all case samples.
No variants following XLD mode of inheritance were identified ( Figure S2 ). The search for the causative genotype under AD mode of inheritance in the affected family members resulted in 20 variants, with 16 of them being deleterious (missense and frameshift variants) ( Figure S2 , Table S1 ). Out of the sixteen variants, two missense variants (Table S1 ) were detected in the RNF213 gene, previously associated with MMD (Kamada et al., 2011; . Both variants were private to the family (with no presence in public databases) and were also found in the unaffected sister (III:8) ( Figure S3 , Table S2 ) supporting incomplete penetrance of the condition. Beside the RNF213 variants, no other candidates that could explain the clinical phenotype were identified in our analysis.
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Variant interpretation
The c.12553A>G (p.(Lys4185Glu)) and c.12562G>A (p.(Ala4185Thr)) variants in affected family members and obligate carriers were observed in the RNF213 gene, which has previously been reported as a major susceptibility gene for MMD (PP4-Supporting) (Kamada et al., 2011; Koizumi et al., 2017) , and have not been published to our knowledge. Both variants were absent from NHLBI Exome Sequencing Project (evs.gs. washington.edu/EVS/), 1000 Genomes Project (1000 Genomes Project Consortium et al., 2015 , or ExAC/gnomAD (Lek et al., 2016) databases (PM2-Moderate) and were private to the family. The RNF213 variants cosegregate with MMD in multiple affected family members (PP1-Supporting) and obligate carriers. Since there are 5 segregations in the family (Supplementary Figure S5) , we upgraded PP1 evidence from default supporting to moderate strength (PP1-Moderate) according to the modified ACMG/AMP criteria for RASopathies (Gelb et al., 2018) . Multiple lines of computational evidence support a deleterious effect of the c.12553A>G variant on the gene product (PP3-Supporting) (Supplementary Table S6 ). A heterozygous missense variant affecting the same lysine residue (c.12554A>C, p.(Lys4185Thr)) has been previously reported for another family of European ancestry with MMD (Smith et al., 2014;  The Human Gene Mutation Database (HGMD) accession CM1414304). The p.(Lys4185Thr) variant has in silico predictions similar to those for p.(Lys4185Glu) ( Supplementary Table S6 ) and is listed as "disease causing" in the HGMD database although no classification according to the ACMG/AMP guidelines is provided. Given that the p.(Lys4185Thr) variant does not meet "likely pathogenic"/"pathogenic" criteria, we downgraded PM5 from default moderate to supporting strength (PM5-Supporting). Since there are 2 moderate and 2 supporting pathogenicity evidence tags, p.(Lys4185Glu) variant in the RNF213 gene is therefore interpreted to be likely pathogenic for MMD and acts in a dominant manner (Supplementary Figure S6) .
For the p.(Ala4185Thr) variant multiple lines of computational evidence suggest limited impact on gene product (BP4-Supporting) ( Supplementary Table S6 ). We interpret p.(Ala4188Thr) variant in the RNF213 gene as a variant of uncertain significance with respect to MMD due to conflicting/insufficient evidence ( 1 supporting benign evidence tag, 1 moderate and 1 supporting pathogenicity evidence tags) (Supplementary Figure S6 ). Total number of identified variants:
148,682
Number of RefSeqGene exonic and splice region variants:
34,863
Number of variants not present or rare (allele frequencies <0.5%) in public databases:
1,936
Number of variants retained based on genotype requirements for AD mode of inheritance:
20
Number of deleterious variants:
16
Number of variants in genes linked to a clinical phenotype:
2 Number of variants on chromosome X:
46
Number of variants retained based on genotype requirements for XLD mode of inheritance:
0 Figure S2 . Variant filtering flowchart. In total 148,682 variants were identified in joint (multi-sample) calling for the sequenced family members. 34,863 variants lied in RefSeqGene exonic and splice regions. Out of these variants, 1,936 were not present or were rare (allele frequencies <0.5%) in public databases. Twenty variants were further retained based on genotype requirements for autosomal dominant (AD) mode of inheritance (see Supplementary Text S1), with 16 variants being deleterious (missense and frameshift variants). Out of the sixteen variants, two were found in the gene (RNF213 ) previously associated with the disease. No variants following X-linked dominant (XLD) mode of inheritance were identified. of other family members were obtained with Sanger sequencing. There are 2 segregations from individual II:7 to II:1 (obligate carrier) and II:8 (obligate carrier), 2 segregations from II:1 to III:1 and III:2 and 1 segregation from II:8 to III:9. Individuals I:2 and III:7 were affected but were not genotyped, so it was not counted as a segregation. Individual III:8 is genotype positive but is not affected probably due to a delayed onset of the disease and was not counted as a segregation either. 
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